Alejandro A Schäffer
Alejandro A Schäffer is an expert in Genetics at National Cancer Institute (United States) (United States). Alejandro A Schäffer has authored 334 publications, the most recent in 2026. SLR score: 1,053 (community average: 125). How the SLR is computed.
LeadR Profile
Genetics
Subspecialties: Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Alejandro Schäffer was born in Montevideo, Uruguay and emigrated with his parents to the United States. He received his B. S. in Applied Mathematics and his M.S. in Mathematics from Carnegie Mellon University in 1983. He received his PhD in Computer Science from Stanford University in 1988, focusing on algorithms and theoretical computer science. In 1992, he switched his research focus to software for genetics.He is best known for leading the development of the genetic linkage analysis package FASTLINK and for doing the implementation of the PSI-BLAST module of the sequence analysis package BLAST. The 1997 paper describing PSI-BLAST and other algorithmic improvements to BLAST is one of the 100 most cited scientific papers of all time. He has also carried out genomic data analysis as one member of large teams doing medical genetics studies, especially studies identifying genes that when mutated cause human primary immunodeficiencies. In 1999, Dr. Schäffer co-authored one of the first papers in tumor phylogenetics, now an active area of research in cancer genomics. Dr. Schäffer has been a Computer Scientist at the National Institutes of Health since 1996, first at the National Center for Human Genome Research which became the National Human Genome Research Institute during 1996-1998, second at the National Center for Biotechnology Information 1998-2018, and currently at the Cancer Data Science Laboratory in NCI which he joined on October 28, 2018. In the Cancer Data Science Laboratory, Dr. Schäffer applies his experience in algorithms, biological sequence analysis, genetic data analysis, and immunology to address research questions in cancer genomics and since 2021 he has also been working on large-scale analysis of cancer clinical trials.
Organizations
Career arc: 1995 - 2026
Number : 334
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Qombucha: Reconstructing unobserved progenitor methylation profiles reveals distinct developmental programs in glioblastoma. PMID 42845327 — cells, brain, neoplasms, stem cells, glioblastoma | bioRxiv | 2026 | 0 |
| Proteomic Profiling Identifies CLDN3 as a Tumor-Selective Therapeutic Target in Small Cell Lung Cancer. PMID 42619739 — cells, lung, neoplasms, proteogenomics, lung neoplasms, small cell lung carcinoma, therapeutics | bioRxiv | 2026 | 0 |
| Bi-allelic missense variants in human GPN2 result in Perrault syndrome. PMID 42392036 — genetics | Am J Hum Genet | 2026 | 0 |
| Trials for Rare Cancers Are More Successful than those for Common Cancers. PMID 42382004 — neoplasms, therapeutics | ESMO Rare Cancers | 2026 | 1 |
| TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens. PMID 42120493 — androgen antagonists, genes, neoplasms, prostate, prostatic neoplasms, therapeutics | EMBO Mol Med | 2026 | 0 |
LeadR Networks
Main global connection map